Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
WHI-P154
Cat. No.:
0225LY-1100
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
WHI-P154 is identified as a potent inhibitor of the JAK3 enzyme.
Synonym:
Jak3 inhibitor ii; 211555-04-3; WHI-P 154; 2-Bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; 2-bromo-4-((6,7-dimethoxyquinazolin-4-yl)amino)phenol; 2-Bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol; 4-(3'-bromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline; 2-bromo-4-(6,7-dimethoxyquinazolin-4-ylamino)phenol; WHIP154
CAS No.:
211555-04-3
Compound CID:
3795
Formula:
C16H14BrN3O3
Formula Weight:
376.2
Specification
Targets&IC50:
Src: 100 nM; EGFR: 4 nM; VEGFR: 100 nM; JAK3: 1.8 μM
Relative Density:
1.576 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
WHI-P154 can be used in kinase studies to examine the potent and selective inhibition of the JAK3 signaling pathway.
Library Information
Target:
EGFR; VEGFR; Src; JAK
Receptor:
EGFR; JAK; JAK3; Src; VEGFR
Pathways:
Stem cell regulation; Apoptosis; Tyrosine kinase/adaptors; Chromatin/Epigenetic; JAK/STAT signaling; Angiogenesis
Plate Number:
AOCL-15
Plate Location:
b6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 132.91 mM
ALogP:
3.95
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
4
